Sanofi
SNY
585 hedge funds and large institutions have $10.7B invested in Sanofi in 2021 Q2 according to their latest regulatory filings, with 61 funds opening new positions, 232 increasing their positions, 157 reducing their positions, and 43 closing their positions.
121% more call options, than puts
Call options by funds: $39M | Put options by funds: $17.6M
48% more repeat investments, than reductions
Existing positions increased: 232 | Existing positions reduced: 157
42% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 43
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
9% more capital invested
Capital invested by funds: $9.77B → $10.7B (+$917M)
2% more funds holding
Funds holding: 572 → 585 (+13)
0.4% more ownership
Funds ownership: 15.66% → 16.06% (+0.4%)
Top Buyers
Top Sellers
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$47.7M |
| 2 |
BlackRock
New York
|
-$29.2M |
| 3 |
Morgan Stanley
New York
|
-$27.2M |
| 4 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
-$19.7M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$16.5M |
SNY Hedge Fund Activity: Q2 2021 in Review
585 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q2 2021, worth a combined $10.7B — up 9.4% from $9.77B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new SNY positions and 43 closed out — a net gain of 18 holders — while 232 added to existing stakes and 157 trimmed.
The largest buyer was Camber Capital Management, opening a new position worth an estimated $117M. The largest seller was Arrowstreet Capital, cutting an estimated $47.7M.
- 585 institutional investors held Sanofi (SNY) as of Q2 2021, up from 572 in Q1 2021.
- Funds reported $10.7B of Sanofi stock for Q2 2021, up 9.4% quarter-over-quarter.
- 61 funds opened new Sanofi positions in Q2 2021 and 43 closed out, a net change of +18 holders.
- The largest Sanofi buyer in Q2 2021 was Camber Capital Management, an estimated $117M added.
- The largest Sanofi seller in Q2 2021 was Arrowstreet Capital, an estimated $47.7M sold.
Based on aggregated 13F filings for Q2 2021.